These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 8643682)

  • 1. Core binding factor beta-smooth muscle myosin heavy chain chimeric protein involved in acute myeloid leukemia forms unusual nuclear rod-like structures in transformed NIH 3T3 cells.
    Wijmenga C; Gregory PE; Hajra A; Schröck E; Ried T; Eils R; Liu PP; Collins FS
    Proc Natl Acad Sci U S A; 1996 Feb; 93(4):1630-5. PubMed ID: 8643682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The leukemic protein core binding factor beta (CBFbeta)-smooth-muscle myosin heavy chain sequesters CBFalpha2 into cytoskeletal filaments and aggregates.
    Adya N; Stacy T; Speck NA; Liu PP
    Mol Cell Biol; 1998 Dec; 18(12):7432-43. PubMed ID: 9819429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical analysis of CBFbeta-SMMHC protein reveals a unique nuclear localization in acute myeloid leukemia with inv(16)(p13q22).
    Zhao W; Claxton DF; Medeiros LJ; Lu D; Vadhan-Raj S; Kantarjian HM; Nguyen MH; Bueso-Ramos CE
    Am J Surg Pathol; 2006 Nov; 30(11):1436-44. PubMed ID: 17063086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The leukemic core binding factor beta-smooth muscle myosin heavy chain (CBF beta-SMMHC) chimeric protein requires both CBF beta and myosin heavy chain domains for transformation of NIH 3T3 cells.
    Hajra A; Liu PP; Wang Q; Kelley CA; Stacy T; Adelstein RS; Speck NA; Collins FS
    Proc Natl Acad Sci U S A; 1995 Mar; 92(6):1926-30. PubMed ID: 7892201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The core binding factor (CBF) alpha interaction domain and the smooth muscle myosin heavy chain (SMMHC) segment of CBFbeta-SMMHC are both required to slow cell proliferation.
    Cao W; Adya N; Britos-Bray M; Liu PP; Friedman AD
    J Biol Chem; 1998 Nov; 273(47):31534-40. PubMed ID: 9813068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multimerization via its myosin domain facilitates nuclear localization and inhibition of core binding factor (CBF) activities by the CBFbeta-smooth muscle myosin heavy chain myeloid leukemia oncoprotein.
    Kummalue T; Lou J; Friedman AD
    Mol Cell Biol; 2002 Dec; 22(23):8278-91. PubMed ID: 12417730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Core-binding factor beta (CBFbeta), but not CBFbeta-smooth muscle myosin heavy chain, rescues definitive hematopoiesis in CBFbeta-deficient embryonic stem cells.
    Miller JD; Stacy T; Liu PP; Speck NA
    Blood; 2001 Apr; 97(8):2248-56. PubMed ID: 11290585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The inv(16) fusion protein associates with corepressors via a smooth muscle myosin heavy-chain domain.
    Durst KL; Lutterbach B; Kummalue T; Friedman AD; Hiebert SW
    Mol Cell Biol; 2003 Jan; 23(2):607-19. PubMed ID: 12509458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of core-binding factor alpha (CBF alpha) reverses cellular transformation by the CBF beta-smooth muscle myosin heavy chain chimeric oncoprotein.
    Hajra A; Liu PP; Speck NA; Collins FS
    Mol Cell Biol; 1995 Sep; 15(9):4980-9. PubMed ID: 7651416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The PEBP2beta/CBF beta-SMMHC chimeric protein is localized both in the cell membrane and nuclear subfractions of leukemic cells carrying chromosomal inversion 16.
    Kanto S; Chiba N; Tanaka Y; Fujita S; Endo M; Kamada N; Yoshikawa K; Fukuzaki A; Orikasa S; Watanabe T; Satake M
    Leukemia; 2000 Jul; 14(7):1253-9. PubMed ID: 10914550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fusion between transcription factor CBF beta/PEBP2 beta and a myosin heavy chain in acute myeloid leukemia.
    Liu P; Tarlé SA; Hajra A; Claxton DF; Marlton P; Freedman M; Siciliano MJ; Collins FS
    Science; 1993 Aug; 261(5124):1041-4. PubMed ID: 8351518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cbfbeta reduces Cbfbeta-SMMHC-associated acute myeloid leukemia in mice.
    Heilman SA; Kuo YH; Goudswaard CS; Valk PJ; Castilla LH
    Cancer Res; 2006 Dec; 66(23):11214-8. PubMed ID: 17145866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The chimeric protein, PEBP2 beta/CBF beta-SMMHC, disorganizes cytoplasmic stress fibers and inhibits transcriptional activation.
    Tanaka Y; Fujii M; Hayashi K; Chiba N; Akaishi T; Shineha R; Nishihira T; Satomi S; Ito Y; Watanabe T; Satake M
    Oncogene; 1998 Aug; 17(6):699-708. PubMed ID: 9715271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytoplasmic sequestration of the polyomavirus enhancer binding protein 2 (PEBP2)/core binding factor alpha (CBFalpha) subunit by the leukemia-related PEBP2/CBFbeta-SMMHC fusion protein inhibits PEBP2/CBF-mediated transactivation.
    Kanno Y; Kanno T; Sakakura C; Bae SC; Ito Y
    Mol Cell Biol; 1998 Jul; 18(7):4252-61. PubMed ID: 9632809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. c-Myc overcomes cell cycle inhibition by CBFbeta-SMMHC, a myeloid leukemia oncoprotein.
    Bernardin F; Yang Y; Civin CI; Friedman AD
    Cancer Biol Ther; 2002; 1(5):492-6. PubMed ID: 12496475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The AML1/ETO(MTG8) and AML1/Evi-1 leukemia-associated chimeric oncoproteins accumulate PEBP2beta(CBFbeta) in the nucleus more efficiently than wild-type AML1.
    Tanaka K; Tanaka T; Kurokawa M; Imai Y; Ogawa S; Mitani K; Yazaki Y; Hirai H
    Blood; 1998 Mar; 91(5):1688-99. PubMed ID: 9473235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting binding partners of the CBFβ-SMMHC fusion protein for the treatment of inversion 16 acute myeloid leukemia.
    Richter L; Wang Y; Hyde RK
    Oncotarget; 2016 Oct; 7(40):66255-66266. PubMed ID: 27542261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HDAC1 Is a Required Cofactor of CBFβ-SMMHC and a Potential Therapeutic Target in Inversion 16 Acute Myeloid Leukemia.
    Richter LE; Wang Y; Becker ME; Coburn RA; Williams JT; Amador C; Hyde RK
    Mol Cancer Res; 2019 Jun; 17(6):1241-1252. PubMed ID: 30814129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization and use of an antibody detecting the CBFbeta-SMMHC fusion protein in inv(16)/t(16;16)-associated acute myeloid leukemias.
    Viswanatha DS; Chen I; Liu PP; Slovak ML; Rankin C; Head DR; Willman CL
    Blood; 1998 Mar; 91(6):1882-90. PubMed ID: 9490670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular basis for a dominant inactivation of RUNX1/AML1 by the leukemogenic inversion 16 chimera.
    Huang G; Shigesada K; Wee HJ; Liu PP; Osato M; Ito Y
    Blood; 2004 Apr; 103(8):3200-7. PubMed ID: 15070703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.